Status:
COMPLETED
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
Lead Sponsor:
Amgen
Collaborating Sponsors:
Immunex Corporation
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to esti...
Eligibility Criteria
Inclusion
- Fulfillment of the 1987 American Rheumatism Association criteria for RA
- Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)
Exclusion
- Currently or previously enrolled in RADIUS 1
- Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol
- Active infections
- Known allergy to ENBREL® or any of its components
- Current treatment with ENBREL®
- Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy
- Nursing or pregnant women
Key Trial Info
Start Date :
October 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
5103 Patients enrolled
Trial Details
Trial ID
NCT00116727
Start Date
October 1 2002
End Date
October 1 2008
Last Update
May 6 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.